NCT04869800已完成1 期
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-398 in Healthy Volunteers Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Cmax of CKD-398
研究概览
简要总结
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-398
详细描述
A randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-398 in healthy volunteers under fasting conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 54 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults age≥19 years and age<55 years at the time of screening
- •Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) < 30.5kg/m2 and men's total body weight ≥ 55 kg, women's total body weight ≥ 45 kg
- •* BMI = Weight(kg)/ Height(m)2
- •Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years
- •Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, urinalysis, viral/ bacterial, etc.) and vital signs, ECG etc. performed at screening
- •Individuals who signed an informed consent form approved by the IRB of Chonbuk National University Hospital and decided to participate in the study after being fully informed of the study prior to participation, including the objective, content and characteristics of the investigational product
- •Individuals who agreed proper contraception during the study and did consent to not donation of sperm 1 month after the last dose of study drug infusion
- •Individuals with the ability and willingness to participate the entire study period
排除标准
- •Individuals with a medical evidence or a history (excluding a dental history of periodontal surgery, impacted wisdom teeth removal, etc.) of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune diseases.
- •Individuals with a medical history of gastrointestinal disease (e.g., gullet disease such as esophageal achalasia and esophagostenosis and Crohn's disease) or operations (excluding simple appendectomy, herniotomy or tooth extraction) that may affect drug absorption.
- •Individuals with the following laboratory test results at screening:
- •ALT or AST > 2x the upper limit of the normal range
- •History of regular alcohol consumption exceeding 210 g/week within the 6 months prior to screening (1 drink (250 mL) of beer (5%) = 10 g; 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL) of wine (12%) = 12 g)
- •Individuals who smoked more than 20 cigarettes per day within 6 months prior to screening
- •Individuals who had been administered investigational product(s) from other clinical study or bioequivalence study within the 6 months prior to the first dose of this study
- •Following vital signs results at screening
- •Sitting systolic blood pressure ≥ 140 mmHg or < 90 mmHg and/or sitting diastolic blood pressure ≥90 mmHg or <60 mmHg
- •Individuals with a medical history of significant alcohol or drug abuse within one year prior to the screening
- •Individuals who had taken any drug(s) known as a strong inducer(s) or inhibitor(s) of drug-metabolizing enzymes within 30 days prior to the first dose of investigational product(s)
- •Individuals who had taken prescription or nonprescription drugs within the 10 days prior to the first dose of investigational product(s)
- •Individuals who donated whole blood within the 2 months, or blood components within 1 month prior to the first dose of the investigational product(s)
- •Individuals with severe acute/chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product(s) administration, or may interfere with the interpretation of study results
- •Individuals with hypersensitivity to investigational products or the investigational products ingredients or dihydropyridine drugs
- •Subject had severe heart failure(NYHA class 1, 2, 3, 4)
- •Patients with hepatopathy
- •Patients with diabetic ketogenic acidosis, diabetic comas and ex-coma, type 1 diabetes.
- •Before and after surgery, severe infections, severe trauma.
- •Patients with edema
- •Subject had renal impairment(eGFR < 60 mL/min/1.73 m²)
- •Subject who is a pregnant or nursing woman
- •Subject had genetic dysfunctions like galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •Subjects who were deemed inappropriate to participate in the study by the investigator
研究组 & 干预措施
Sequence 1
Experimental
- Period 1: Reference drug(CKD-501, D745)
- Period 2: Test drug(CKD-398)
干预措施: CKD-398 (Drug)
Sequence 1
Experimental
- Period 1: Reference drug(CKD-501, D745)
- Period 2: Test drug(CKD-398)
干预措施: CKD-501, D745 (Drug)
Sequence 2
Experimental
- Period 1: Test drug(CKD-398)
- Period 2: Reference drug(CKD-501, D745)
干预措施: CKD-398 (Drug)
Sequence 2
Experimental
- Period 1: Test drug(CKD-398)
- Period 2: Reference drug(CKD-501, D745)
干预措施: CKD-501, D745 (Drug)
结局指标
主要结局
Cmax of CKD-398
时间窗: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose
The maximum concentration observed of CKD-344 over blood sampling time.
AUCt of CKD-398
时间窗: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose
Area under the plasma concentration time curve of CKD-344, from time zero up to the last measurable concentration.
次要结局
- AUCinf of CKD-398(predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose)
- T1/2 of CKD-398(predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose)
- Tmax of CKD-398(predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose)
- CL/F of CKD-398(predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose)
- Vd/F of CKD-398(predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348Hypertension and DyslipidemiaNCT04587206Chong Kun Dang Pharmaceutical62
已完成
1 期
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348Hypertension and DyslipidemiaNCT04660370Chong Kun Dang Pharmaceutical70
已完成
1 期
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)Hypertension and DyslipidemiaNCT05192356Chong Kun Dang Pharmaceutical63
已完成
1 期
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mgHypertension and DyslipidemiaNCT05698043Chong Kun Dang Pharmaceutical63
已完成
1 期
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)Hypertension and DyslipidemiaNCT04694989Chong Kun Dang Pharmaceutical62